Pharmacokinetic Evaluation of 99mTc-radiolabeld Solid Lipid Nanoparticles and Chitosan Coated Solid Lipid Nanoparticles.
Solid Lipid Nanoparticles (SLNs) possess unique in vivo features such as high resistivity, bioavailability and habitation at the target site. Coating nanoparticles with polymers such as chitosan greatly affects their pharmacokinetic behavior, stability, tissue uptake, and controlled drug-delivery. The aim of this study was to prepare and evaluate the biodistribution of 99mTc-labeled SLNs and chitosan modified SLNs in animals. 99mTc-oxine was prepared and utilized to radiolabel pre-papered SLNs or chitosan coated SLNs. After purification of radiolabeled SLNs (99mTc-SLNs) and radiolabeled chitosan coated SLNs (99mTc-Chi-SLNs) using Amicon filter, they were injected into BALB/c mice to evaluate their biodistribution patterns. In addition, nanoparticles were characterized using Transmission Electron Microscopy (TEM), Fourier-transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray Powder Diffraction (XRD) and Dynamic Light Scattering (DLS). 99mTc-oxine with high radiochemical purity (RCP~100%) and stability (RCP > 97% at 24 h) was used to provide 99mTc-SLNs and 99mTc-Chi-SLNs with high initial RCP (100%). TEM image and DLS data suggest 99mTc-SLNs susceptibility to aggregation. To that end, main portion of 99mTc-SLNs radioactivity accumulates in liver and intestines, while 99mTc-Chi-SLNs sequesters in liver, intestines and kidneys. The blood radioactivity of 99mTc-Chi-SLNs was higher than that of 99mTc-SLNs by 7.5, 3.17 and 3.5 folds at 1, 4 and 8 h post-injection. 99mTc-Chi-SLNs uptake in the kidneys in comparison with 99mTc-SLNs was higher by 37.48, 5.84 and 11 folds at 1, 4 and 8 h. Chitosan layer on the surface of 99mTc-Chi-SLNs reduces lipophilicity in comparison with 99mTc-SLNs. Therefore, 99mTc-Chi-SLNs is less susceptible to aggregation, which leads to its lower liver uptake and higher kidney uptake and blood concentration.